Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Wor
about
Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)DPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variantsK65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenineIdentification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidineResistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptaseNovel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolatesU-90152, a potent inhibitor of human immunodeficiency virus type 1 replicationAnti-human immunodeficiency virus 1 (HIV-1) activities of 3-deazaadenosine analogs: increased potency against 3'-azido-3'-deoxythymidine-resistant HIV-1 strainsGenotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitorAntiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitorCharacterization of siamycin I, a human immunodeficiency virus fusion inhibitorThe nucleoside analog-resistant E89G mutant of human immunodeficiency virus type 1 reverse transcriptase displays a broader cross-resistance that extends to nonnucleoside inhibitorsEscape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness lossTwo HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entryA synthetic HIV-1 subtype C backbone generates comparable PR and RT resistance profiles to a subtype B backbone in a recombinant virus assayThe Antiviral Activity of Approved and Novel Drugs against HIV-1 Mutations Evaluated under the Consideration of Dose-Response Curve SlopeThe Cellular Thioredoxin-1/Thioredoxin Reductase-1 Driven Oxidoreduction Represents a Chemotherapeutic Target for HIV-1 Entry InhibitionA recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors.The phthalocyanine prototype derivative Alcian Blue is the first synthetic agent with selective anti-human immunodeficiency virus activity due to its gp120 glycan-binding potential.HIV-1 clade B Tat, but not clade C Tat, increases X4 HIV-1 entry into resting but not activated CD4+ T cells.Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine.Line probe assay for detection of human immunodeficiency virus type 1 mutations conferring resistance to nucleoside inhibitors of reverse transcriptase: comparison with sequence analysisRapid ganciclovir susceptibility assay using flow cytometry for human cytomegalovirus clinical isolates.Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group.Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapyDecreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.Functional correlates of insertion mutations in the protease gene of human immunodeficiency virus type 1 isolates from patients.Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations.Monitoring patients with HIV diseaseDetection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing.Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase.Human immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing.ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team.A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5)Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure.Hormonally active vitamin D3 (1alpha,25-dihydroxycholecalciferol) triggers autophagy in human macrophages that inhibits HIV-1 infection.Phenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine.
P2860
Q28343932-4C75E810-96B5-4432-9FEA-52B40596329AQ28361560-FF7B53FC-7E3C-4F25-8F7F-41CBF7E7E6FEQ28367386-BC40D5E4-EE01-43EB-B973-753630A69449Q28367543-3216D50A-1A7E-4488-81D3-3694A5402BBEQ28367547-BDC3CD7C-79AF-434C-8EDD-5270B2D12BA8Q28367722-470BE044-ACCC-4CFC-8473-5BE60F47580EQ28368034-35EFDA0E-A0EA-4D26-9FF5-616F6BC349C1Q28368280-509C0B60-3073-42C8-ABCE-E76FFCA2A7E8Q28369030-092680ED-9D94-4C0B-BAAE-BB1934C69FAAQ28369528-9849A909-135E-4F29-BA38-D430BAB7D649Q28378892-A315F89B-0F78-492E-935C-1886921E1B18Q28379084-99C810B2-44B5-4F8A-BCBB-068F843CD98EQ28379139-F89EC410-0C27-4682-916F-ACB0567E3133Q28469223-622E119C-794A-4F2D-95DC-4D500DB0225CQ28475912-DBFE3A4F-F0F8-4075-8306-AA96742F0AB5Q28478253-0F336EE2-0821-4B2E-8F5C-F92CDE0B01E7Q28550441-4AB8BAE2-5ACA-47E0-9FDE-BE34D0D16024Q28552932-801E11E0-7635-4DAD-B3C6-880B9F1BDB7DQ32157822-8D31DA3C-F4BB-44AE-A132-56198E13A14EQ33498727-E8032728-B1BD-402C-BC36-5A45D563EF8AQ33581852-374D714F-E624-4440-B438-84E01CAC8E73Q33657585-37C9E789-9534-408A-A193-29CD2A43A7B7Q33675233-B383569C-5AF1-45D8-A711-E2320E5697CFQ33696787-78A4F8DD-50B7-4ACA-99DC-3BA45430174DQ33749177-672054DC-84C8-447D-AE25-84D69A64435DQ33782492-A0CCBFEB-768D-44AE-BEF5-E8B60F537686Q33820365-5F999999-5258-4D62-9C57-0548E3971E21Q33849423-EA0E6287-7453-4BF9-9F79-B82BCF3469B9Q33851627-231EC182-88AC-4C62-BB69-F856C204E609Q33872810-3263C7C3-26DA-4DB2-90BA-1D665ED5AA6DQ33925492-C7DBFEA4-916A-4DF6-AFE7-B260458DB892Q33951977-D4A8B27D-3D84-4A04-9E2A-AB0D4702CCC2Q33961507-53625909-5A21-4847-AE16-53D3DCFF23B0Q33962513-D268D375-CCA4-46C1-BC8F-7EDCF01EF26FQ33976896-CCF4F344-6A11-4587-AFF2-9CEEAE023DA8Q33979107-292DA2AA-A8C4-4529-82D3-58F6FB6365D2Q33981401-EB2CBCF6-A4FF-4408-AD1F-EBE80F518677Q34120736-980B7F0D-DB47-4B66-B0E4-FB74818C3961Q34174790-E50BF1C6-5D19-4C00-A7DA-840F8639BC35Q34251987-14C06FFF-07CD-4395-9A13-C5876AB6E414
P2860
Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Wor
description
1993 nî lūn-bûn
@nan
1993 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Standardized peripheral blood ...... ology Committee Resistance Wor
@nl
type
label
Standardized peripheral blood ...... ology Committee Resistance Wor
@nl
prefLabel
Standardized peripheral blood ...... ology Committee Resistance Wor
@nl
P2093
P2860
P3181
P356
P1476
Standardized peripheral blood ...... ittee Resistance Working Group
@en
P2093
A J Japour
D L Mayers
D R Kuritzkes
J M Arduino
L A Beckett
P S Reichelderfer
R T D'Aquila
V A Johnson
P2860
P304
P3181
P356
10.1128/AAC.37.5.1095
P407
P577
1993-05-01T00:00:00Z